Boettcher BT, Woehlck HJ, Makker H, Pagel PS, Freed JK. Hydroxocobalamin for treatment of catecholamine-resistant vasoplegia during liver transplantation: A single-center series of 20 cases.
Int J Surg Case Rep 2022;
98:107488. [PMID:
35981485 PMCID:
PMC9399471 DOI:
10.1016/j.ijscr.2022.107488]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Revised: 08/03/2022] [Accepted: 08/07/2022] [Indexed: 11/25/2022] Open
Abstract
Introduction
Catecholamine-resistant vasoplegia is a potentially devastating complication during liver transplantation. Hydroxocobalamin has emerged as a treatment for vasoplegia associated with cardiac surgery, liver transplantation, and septic shock.
Presentation of case
We performed a retrospective review of patients who underwent liver transplantation between October 2015 and May 2020 to evaluate the efficiency of hydroxocobalamin in this setting.
Discussion
A total of 137 patients underwent liver transplantation, of which 20 received hydroxocobalamin for vasoplegia. Administration of hydroxocobalamin increased mean arterial pressure and reduced vasoactive drug requirements.
Conclusion
This case series adds to the previous individual reports describing the use of hydroxocobalamin during liver transplantation suggesting hydroxocobalamin can mitigate refractory hypotension from catecholamine resistant vasoplegia during liver transplantation.
Hypotension or vasoplegia is commonly encountered in end-stage liver disease.
Vasoplegia during liver transplant is a common and potentially devastating condition.
Hydroxocobalamin has been reported to improve catecholamine resistant vasoplegia.
Hydroxocobalamin is believed to work by scavenging gasotransmitters NO, CO, and H2S.
Collapse